<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471246</url>
  </required_header>
  <id_info>
    <org_study_id>20200175</org_study_id>
    <nct_id>NCT04471246</nct_id>
  </id_info>
  <brief_title>High-dose vs. Standard-dose Cephalexin for Cellulitis</brief_title>
  <official_title>High-dose Cephalexin for Cellulitis: A Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ottawa Hospital Academic Medical Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Association of Emergency Physicians</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Cellulitis is a common clinical condition that represents up to 3% of all
      emergency department (ED) visits. The current treatment failure rate is approximately 20%.
      This high treatment failure rate may be due to suboptimal dosing of cephalexin. The
      Investigators hypothesize that high-dose cephalexin may lead to lower rates of treatment
      failure and subsequently improved patient outcomes (less hospitalizations and avoidance of
      intravenous antibiotics)

      Rationale: Before embarking on a large, multicenter trial, it is essential to conduct a
      smaller pilot to test and refine study procedures and to demonstrate feasibility.

      Methods:

      Design: The investigators will conduct a parallel arm double-blind randomized controlled
      pilot trial at the Civic and General campus ED of The Ottawa Hospital (TOH). The study will
      operate seven days a week from 0800 to 2000 over a 6-month timeframe. TOH Pharmacy will
      follow a randomization sequence and prepare and dispense study medication packages.

      Patients: Adult (age &gt;=18 years) ED patient with non-purulent cellulitis determined by the
      treating emergency physician to be eligible for outpatient care with oral antibiotics.

      Intervention: High-dose cephalexin (1000 mg PO QID) for seven days.

      Comparator: Standard-dose cephalexin (500 mg PO QID) plus placebo for seven days.

      Primary Feasibility Outcome: Patient recruitment rate (percentage of approached eligible
      patients who are successfully recruited). The goal is to recruit at least 29% of eligible
      patients.

      Primary Effectiveness Outcome: Oral antibiotic treatment failure, defined as a change to (i)
      outpatient intravenous therapy; or (ii) hospitalization for intravenous therapy. This change
      to intravenous therapy must be due to worsening infection, defined as: (i) increasing lesion
      area; (ii) worsening pain (visual analog scale); or (iii) any two of fever, tachypnea or
      tachycardia.

      Importance: This pilot trial will be the first to compare high-dose cephalexin to
      standard-dose cephalexin for ED patients with cellulitis. The results of this pilot
      randomized trial will help inform the design and implementation of a larger, multicenter
      randomized controlled trial to answer this important clinical question.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The Investigators will conduct a parallel arm double-blind randomized controlled pilot trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Eligible patients will be randomized (1:1) to high-dose versus standard-dose arms. The randomization sequence will be computer-generated by a statistician</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient recruitment rate</measure>
    <time_frame>6 months</time_frame>
    <description>% of patients recruited into the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral antibiotic treatment failure</measure>
    <time_frame>6 months</time_frame>
    <description>% of patients with oral antibiotic treatment failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ability to approach eligible patients</measure>
    <time_frame>6 months</time_frame>
    <description>% of eligible patients that are approached for consent to enter into the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of blinding</measure>
    <time_frame>7 days</time_frame>
    <description>Assessment of blinding via a patient questionnaire (participant will be asked to indicate which treatment they believe they received) at end of therapy (7 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protocol adherence</measure>
    <time_frame>7 days</time_frame>
    <description>% of patients that are adherent to allocated treatment for 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss to follow up</measure>
    <time_frame>14 days</time_frame>
    <description>% of patients lost to follow up at 14 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>7 days</time_frame>
    <description>% of patients with clinical cure (no erythema, pain and fever) at days 3 and 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>% of patients with adverse events (e.g. vomiting, diarrhea, rash) at 14-days measured via telephone follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned ED Visits or Hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>% of patients with unplanned i) return ED visits; and ii) hospitalization, measured via 14-day telephone follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Cellulitis</condition>
  <arm_group>
    <arm_group_label>High Dose Cephalexin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention is high-dose cephalexin (1000mg PO QID) for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Dose Cephalexin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator is standard-dose cephalexin (500mg PO QID) plus oral placebo for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>1000 mg PO QID for 7 days</description>
    <arm_group_label>High Dose Cephalexin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>500 mg PO QID plus oral placebo for 7 days</description>
    <arm_group_label>Standard Dose Cephalexin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adults (age &gt;=18 years) with non-purulent cellulitis determined by the treating emergency
        physician to be eligible for outpatient care with oral antibiotics.

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Patient already taking oral antibiotics

          3. Treating physician decides that intravenous therapy is required

          4. Abscess requiring an incision and drainage or needle aspiration procedure

          5. Known prior cellulitis secondary to methicillin-resistant Staphylococcus aureus

          6. Cellulitis secondary to a human or animal bite wound

          7. Surgical site infection

          8. Malignancy and currently being treated with chemotherapy

          9. Febrile neutropenia (temperature &gt;=38C plus absolute neutrophil count &lt;500 cells/uL)

         10. Solid organ or bone marrow transplant recipient

         11. Renal impairment with creatinine clearance &lt;30 mL/min

         12. Pregnant or breastfeeding

         13. Allergy to cephalosporins or history of anaphylaxis to penicillin

         14. Inability to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krishan Yadav, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krishan Yadav, MD</last_name>
    <phone>613-798-5555</phone>
    <email>kyadav@toh.ca</email>
  </overall_contact>
  <results_reference>
    <citation>Stevens DL, Eron LL. In the clinic. Cellulitis and soft-tissue infections. Ann Intern Med. 2009 Jan 6;150(1):ITC11. Review.</citation>
    <PMID>19124814</PMID>
  </results_reference>
  <results_reference>
    <citation>Stenstrom R, Grafstein E, Romney M, Fahimi J, Harris D, Hunte G, Innes G, Christenson J. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department. CJEM. 2009 Sep;11(5):430-8. Erratum in: CJEM. 2009 Nov;11(6):570.</citation>
    <PMID>19788787</PMID>
  </results_reference>
  <results_reference>
    <citation>Yadav K, Suh KN, Eagles D, MacIsaac J, Ritchie D, Bernick J, Thiruganasambandamoorthy V, Wells G, Stiell IG. Predictors of Oral Antibiotic Treatment Failure for Nonpurulent Skin and Soft Tissue Infections in the Emergency Department. Acad Emerg Med. 2019 Jan;26(1):51-59. doi: 10.1111/acem.13492. Epub 2018 Jul 4.</citation>
    <PMID>29869364</PMID>
  </results_reference>
  <results_reference>
    <citation>Pollack CV Jr, Amin A, Ford WT Jr, Finley R, Kaye KS, Nguyen HH, Rybak MJ, Talan D. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015 Apr;48(4):508-19. doi: 10.1016/j.jemermed.2014.12.001. Epub 2015 Jan 17. Review.</citation>
    <PMID>25605319</PMID>
  </results_reference>
  <results_reference>
    <citation>Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu444. Erratum in: Clin Infect Dis. 2015 May 1;60(9):1448. Dosage error in article text.</citation>
    <PMID>24973422</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwak YG, Choi SH, Kim T, Park SY, Seo SH, Kim MB, Choi SH. Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection. Infect Chemother. 2017 Dec;49(4):301-325. doi: 10.3947/ic.2017.49.4.301.</citation>
    <PMID>29299899</PMID>
  </results_reference>
  <results_reference>
    <citation>Li HK, Agweyu A, English M, Bejon P. An unsupported preference for intravenous antibiotics. PLoS Med. 2015 May 19;12(5):e1001825. doi: 10.1371/journal.pmed.1001825. eCollection 2015 May.</citation>
    <PMID>25992781</PMID>
  </results_reference>
  <results_reference>
    <citation>Cyriac JM, James E. Switch over from intravenous to oral therapy: A concise overview. J Pharmacol Pharmacother. 2014 Apr;5(2):83-7. doi: 10.4103/0976-500X.130042. Review.</citation>
    <PMID>24799810</PMID>
  </results_reference>
  <results_reference>
    <citation>Yadav K, Gatien M, Corrales-Medina V, Stiell I. Antimicrobial treatment decision for non-purulent skin and soft tissue infections in the emergency department. CJEM. 2017 May;19(3):175-180. doi: 10.1017/cem.2016.347. Epub 2016 Aug 17.</citation>
    <PMID>27531595</PMID>
  </results_reference>
  <results_reference>
    <citation>Chow M, Quintiliani R, Cunha BA, Thompson M, Finkelstein E, Nightingale CH. Pharmacokinetics of high-dose oral cephalosporins. J Clin Pharmacol. 1979 Apr;19(4):185-94.</citation>
    <PMID>438352</PMID>
  </results_reference>
  <results_reference>
    <citation>Wise R. The pharmacokinetics of the oral cephalosporins--a review. J Antimicrob Chemother. 1990 Dec;26 Suppl E:13-20. Review.</citation>
    <PMID>2292525</PMID>
  </results_reference>
  <results_reference>
    <citation>Murray H, Stiell I, Wells G. Treatment failure in emergency department patients with cellulitis. CJEM. 2005 Jul;7(4):228-34.</citation>
    <PMID>17355677</PMID>
  </results_reference>
  <results_reference>
    <citation>Peterson D, McLeod S, Woolfrey K, McRae A. Predictors of failure of empiric outpatient antibiotic therapy in emergency department patients with uncomplicated cellulitis. Acad Emerg Med. 2014 May;21(5):526-31. doi: 10.1111/acem.12371.</citation>
    <PMID>24842503</PMID>
  </results_reference>
  <results_reference>
    <citation>Yadav K, Nath A, Suh KN, Sikora L, Eagles D. Treatment failure definitions for non-purulent skin and soft tissue infections: a systematic review. Infection. 2020 Feb;48(1):75-83. doi: 10.1007/s15010-019-01347-w. Epub 2019 Aug 5.</citation>
    <PMID>31378847</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

